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responsibility of InAbstract The aim of this research was to evaluate doxorubicin (DOX)-loaded zein in situ gels, a new
drug delivery system in which a liquid state drug can be transformed into semi-solid after intratumoral
injection. In vitro release of DOX-loaded zein was investigated and the pharmacokinetics, biodistribution
and therapeutic efﬁcacy of these DOX-loaded zein formulations were investigated using BALB/c nude
tumor-bearing mice. In vitro release of DOX from the gels extended up to 7 days. Efﬁcient accumulation
of DOX in the tumor with lower drug concentration in blood and normal organs was obtained resulting
in effective inhibition of tumor growth and fewer off-target side effects. In conclusion, a DOX-loaded
in situ gel was developed with sustained release, enhanced anti-cancer efﬁcacy for colorectal cancer in vivo,
and especially with reduced off-target side effects.
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Colorectal cancer (CRC) is one of the most frequent cancers
worldwide and is a leading cause of cancer mortality1.
Doxorubicin (DOX) is widely used for the treatment of a
number of cancers, but its usage has been limited due to
cardiotoxic effects2. Considerable effort has been put forth in
the development of drug delivery systems (DDS) for DOX3,4
to change tissue selectivity and improve the toxicity proﬁle.
The increased permeability of blood vessels and the lack of
lymphatic vessels in tumors leads to high hydrostatic pressure
in tumor stroma. Therefore, drugs cannot be effectively
delivered to the tumor tissues by systemic administration5,6.
In order to eliminate these problems, efforts have been focused
on development of the targeting DDS that achieves site-
speciﬁc delivery and prolongs the exposure7,8. During the
last decade, injectable in situ forming gels, as polymeric drug
carriers, have attracted considerable attention9. For CRC,
local injection of in situ gels can be applied by a Sigmoido-
scope. Applications of the in situ gels provide a number of
advantages, including easy application, localized delivery,
prolonged delivery periods, decreased body drug dosage and
improved patient compliance10–12; however, the great majority
of the polymers require artiﬁcial synthesis.
Zein, a major storage protein comprising about 45–50% of
total protein in corn13, was a promising biomaterial with good
biocompatibility for tissue engineering14. As indicated by
SDS-PAGE in the present study, biochemically pure zein is
mainly composed of two distinct bands with molecular
weights of 23 and 21 kDa, with minor bands at 13 and
9.6 kDa. The high proportion of non-polar amino acids in
zein determines its solubility behavior. The molecular struc-
ture is a helical wheel conformation where nine homologous
repeating units are arranged in an anti-parallel form stabilized
by hydrogen bonds15. Zein has been used to form micro-
spheres by cross linking a zein solution containing the drug16.
In order to increase the drug concentration in tumor and
hence to improve the antitumor potency of DOX, DOX-
loaded zein in situ gel was developed in this study. In vitro
release of DOX-loaded zein was investigated and the pharma-
cokinetics, biodistribution and therapeutic efﬁcacy of these
DOX-loaded zein formulations were investigated using
BALB/c nude tumor-bearing mice.2. Materials and methods
2.1. Materials and chemicals
DOX hydrochloride was obtained from Lingnan Pharmaceutical,
Ltd. (Guangzhou, China). Zein was from Rixing Pharmaceutical
Adjuvant Factory (Gaoyou, China). Glycerol formal (GF)
was purchased from AcrosOrganics (Geel, Belgium). All other
chemicals were purchased from Tedia company (Fairﬁeld, USA)
and of HPLC or analytical grade.2.2. Sample preparation
Zein was dissolved mixed with GF and 70% ethanol-water
(3:7, v/v). The concentration of Zein was 15%, 20%, 25% for
in vitro release and 20% for in vivo study. It was left overnightat room temperature to form a clear solution. DOX was added
into the above solution and dissolved by stirring.
2.3. Tumor homograft
The HT-29 cells (human colorectal cancer cell line, Cell Bank
of Peking Union Medical College) were harvested with 0.25%
trypsin and made into suspension (1.0 107 cells/mL). The cell
suspension was implanted subcutaneously into one forefoot
armpit of immunodeﬁcient mice (BALB/c nude mice) (Vital
River, China).
2.4. In vitro DOX release
Half a milliliter of the sample was added to 10 mL PBS (pH 7.4)
containing NaN3 (0.05%, w/v) and trypsin 1:250 (1.0%, w/v)
17,18.
The gels formed were shaken in a constant temperature oscillator
at 50 rpm and 37 1C. 5 mm of the buffer was collected at
predetermined time intervals and replaced with fresh buffer. Drug
concentration was analyzed by HPLC.
2.5. In vivo antitumor efﬁcacy test
When the tumor volume reached approximately 100 mm3 on
the 7th day after cell injection, the mice were randomly divided
into 4 groups (n¼6): (1) normal saline (control), (2) aqueous
solution of DOX, (3) blank gel only, (4) doxorubicin-loaded
zein in situ gels (DOX-zein). The dosages of DOX for a mouse
were set at 5 mg/kg. Gels or solutions were administered using
a 22 G needle. The tumor diameters were measured in two
dimensions every other day with the Somatom sensation
64 CT machine (Siemens, Germany) with automatic 3D
reconstructions.
2.6. Plasma concentration and tissue distribution
When the tumor volume had reached about 100 mm3, the mice
were divided into two groups: (1) aqueous solution of DOX
(i.v.) and (2) DOX-zein (intratumoral injection). The same
dose of 5 mg/kg DOX was injected. At 1, 3, 5, 12, 24, 48, 72 h
after injection the mice were killed. The heart, liver, spleen,
lungs, kidneys and tumors were immediately removed,
cleaned, weighed and homogenized with citric acid-buffered
saline (CBS, pH 8.0, 0.5 mL/g tissue).
The drug was extracted with chloroform-methanol (4:1, v/v)
from plasma diluted with CBS (pH 8.0) and tissues homo-
genized with the same buffer. The organic phase was dried
under N2 at room temperature. The residues were dissolved in
methanol for HPLC analysis (Hitachi, L-2000, Japan). The
AUCs of DOX in the plasma and tissues were calculated
by DAS Ver1.0. The in vivo data was evaluated using Student’s
t-test and Po0.05 was considered to be statistically signiﬁcant.
2.7. HPLC method
The HPLC analysis was performed under the same conditions
as for the release test and tissue and plasma concentration
tests on a Hitachi HPLC system (L-2000, Japan) controlled by
D-2000 workstation using a C18 column (Thermo Hypersil
ODS, 5 mm, 200 mm 4.6 mm). The mobile phase consisting
of 0.01 M ammonium dihydrogen phosphate, methanol,
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of 1.0 mL/min. Detection was at the wavelengths of maximum
absorption of the doxorubicine in the mobile phase at 254 nm.
The instrument room was maintained at 30 1C. The injection
volume was 20 mL. The intra-day and inter-day coefﬁcient of
variations (CVs) of each tissue and plasma were less than
10%. The limit of quantitation (LOQ) was 0.031 mg/mL for
plasma, 0.186 mg/mL for heart, 0.035 mg/mL for liver,
0.086 mg/mL for spleen, 0.064 mg/mL for lung, 0.036 mg/mL
for kidney and 0.027 mg/mL for tumor.Figure. 1 In vitro release of DOX from in situ gel with different
loadings of the drug (n¼3).
Figure. 2 In vitro release of DOX from in situ gel with different
amounts of zein (n¼3).
Figure. 3 Tumor growth after injection for 15 days.3. Results and discussion
3.1. Preparation of an injectable in situ forming gel
The formulation of the in situ gel should have an optimum
viscosity so that it may be easily injected as a liquid and undergo a
rapid sol–gel transition. In addition, the formed gel should
preserve its integrity to facilitate local sustained release of drugs
rather than dissolve or erode quickly. Gel solutions containing
DOX attained the gel state almost immediately after being injected
into the subcutaneous dorsum of mice. The gel-forming ability of
zein can be explained as follows: the molecular structure of zein
was a helical wheel conformation in which nine homologous
repeating units were arranged in an anti-parallel form stabilized by
hydrogen bonds15. After the zein in situ gel solution was injected
into the tumor, the solvent composition at the aqueous interface
was changed, GF diffused away from the depot and water infused
in, resulting in increased concentration of zein at the aqueous
interface. When the concentration of zein reached a critical value
the proteins agglomerated and hydrogen bonding, disulﬁde bond-
ing and hydrophobic interactions between protein molecules
occurred. This maintained the meshwork and led to the formation
of zein gel18.
According to previous results from our laboratory,18 gel
viscosity (130–200 mPa  s) was favorable when the content of
zein was below 30% (w/w) and the formulation was easily
injectable through 26-gauge needles. The proposed content of
macromolecular protein zein is 15–25%. The solvent GF can
slightly increase the viscosity, resulting in a more stabilized
system without sedimentation.
3.2. In vitro DOX release
The in vitro DOX release behavior of gels prepared with DOX at
0.2, 0.4, and 0.8 mg/mL was examined. Fig. 1 shows the release
proﬁles for 7 days. The DOX was released rapidly on the ﬁrst day
followed by a sustained release for the following 6 days, and all
formulations showed incomplete release on 7th day. Drug-loading
had no signiﬁcant effect on in vitro release. Fig. 2 indicates that
higher protein concentration decreased burst release and extended
in vitro release with higher viscosity of the gel depot. Considering
the release proﬁle and viscosity, a zein concentration of 20%
(w/w) was chosen for in vivo study.
For a water-miscible solvent like ethanol, a relatively faster
phase inversion was found, resulting in a porous, rubbery gel
structure. Its release proﬁle was characterized by an initial burst
followed by a slow-release rate for a long period. However, as a
whole, the burst effect was low and tolerable, because the
Pharmacopoeia of the People’s Republic of China (2010. appendix
XIX E)19 has given the limit of less than 40% release in ﬁrst halfan hour. On the other hand, solvents that have relatively low
solvent afﬁnity, such as GF, resulted in a relatively slower phase
inversion and a less porous structure. A solvent system20 was
composed of both hydrophilic (e.g., ethanol and benzyl alcohol)
and hydrophobic (e.g., benzyl benzoate and sucrose acetate
isobutyrate) components. The hydrophilic solvent can decrease
the viscosity of gel, thus facilitating injection and resulting in a
‘‘coat’’ around the exterior of the depot. The hydrophobic solvent
could slow down water penetration and therefore decreases the
protein hydrolysis.
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The in vivo antitumor effect of DOX-zein was evaluated using
BALB/c nude mice inoculated with human colon cancer cells. The
tumor volume was measured by CT scanning 3D reconstruction.
As shown in Fig. 3 in mice injected with saline or gel solution, the
size of the tumor was steadily increased as a function of time,
reaching 20 times of the original size after 15 days without
a signiﬁcant difference between these two groups (P40.05).Figure. 4 Plasma concentration–time curves of DOX in plasma
after single dose of 5 mg/kg DOX (n¼3).
Table 1 Standard curves of doxorubicin (DOX)
Tissue Equation of standard curve
Heart y¼2 104xþ0.1772
Liver y¼5 104xþ0.1526
Spleen y¼8 104x0.0176
Lung y¼1 104x0.1591
Kidney y¼3 104xþ0.2415
Tumor y¼8 105xþ0.0852
Plasma y¼2 105xþ0.0079
x represents peak area of the sample, y represents the
Table 2 The concentrations of doxorubicin (DOX) in differe
(Mean7SD, n¼3).
Time (h) DOX Tissue (mg/g)
Heart Liver Sp
1 Solution 4.8870.57 1.6870.43 0.7
Zein 4.8970.54 N.D. N.
3 Solution 2.8470.65 0.4970.21 0.2
Zein 2.7870.34 0.5370.23 N.
5 Solution 1.7370.35 0.8870.15 0.7
Zein 1.3370.51 0.6070.15 1.4
12 Solution 1.8370.51 0.8370.38 1.0
Zein 0.9570.21 N.D. N.
24 Solution 1.5170.38 0.4270.15 1.3
Zein N.D. N.D. N.
48 Solution N.D. 0.1170.06 0.3
Zein N.D. N.D. N.
72 Solution N.D. N.D. N.
Zein N.D. N.D. N.
N.D.: not detected.Both single injection of DOX-zein and free DOX produced
signiﬁcantly inhibitory effects (Po0.05) against the tumor and
decreased its propagation remarkably. Compared with free drugs,
DOX-zein enhanced the antitumor effect (Po0.01) as shown in
Fig. 3.
3.4. Plasma pharmacokinetics
The DOX solution was injected into the tail vein of a group of
model mice (n¼3) while the DOX-zein gel was injected into
the tumor of another group (n¼3). The plasma concentration
vs. time proﬁle of DOX is presented in Fig. 4. Not surpris-
ingly, the drug concentration in blood of the DOX-zein group
was less than that of the DOX solution group. The AUC of
DOX-zein group and DOX solution group was 9.12 mg/mL  h
and 35.94 mg/mL h, respectively. The liquid state of the DOX-
zein changed to solid state after injection and formed a drug
reservoir, which reduced the chance that the drug entered the
blood and resulted in a sustained release within the tumor.
3.5. Distribution study
To study the drug distribution in animal tissues, saline
(control), blank gel, DOX solution and DOX-zein were
injected into female BALB/c nude mice bearing tumors within different tissues.
Linear range R2
0.5–5.0 mg/mg 0.9938
0.1–2.0 mg/mg 0.9920
0.1–2.0 mg/mg 0.9956
0.1–3.6 mg/mg 0.9925
0.05–2.0 mg/mg 0.9924
0.1–5.0 mg/mg 0.9916
0.1–3.0 mg/mL 0.9936
concentration of DOX.
nt tissues after injection of DOX solution and DOX-zein
leen Lung Kidney Tumor
770.23 1.8570.25 1.4570.39 4.0370.24
D. N.D. N.D. 4.5270.37
70.11 0.8870.15 0.2070.06 2.4670.46
D. 0.7770.18 0.4470.17 3.5170.46
270.32 1.6970.37 0.7270.16 1.0570.26
070.17 N.D. 0.09770.04 4.2170.17
270.18 2.0070.32 0.7570.14 0.7770.31
D. N.D. N.D. 2.8070.62
270.46 1.0970.24 0.1970.08 0.3670.18
D. N.D. 0.1470.08 2.1370.42
670.12 0.1670.08 0.1270.06 0.1070.04
D. N.D. 0.09770.04 2.2270.36
D. 0.1570.09 0.1470.08 0.09670.03
D. N.D. 0.1270.08 1.1270.15
Table 3 Areas under curve of doxorubicin (DOX)
in different tissues after injection of DOX solution and
DOX-zein.
Tissue AUC0t (mg/mL  h)
DOX solution DOX-Zein
Heart 57.40 43.08
Liver 25.62 –
Spleen 44.36 –
Lung 58.61 –
Kidney 25.33 8.95
Tumor 18.71 204.59
Ning Shen et al.614diameter of 7–9 mm. DOX concentrations in tissues were
determined by HPLC. A standard curve for each tissue was
established by adding series concentrations of DOX to tissue
extracts from control group of mice (Table 1). As shown in
Tables 2 and 3, the drug concentration of DOX solution group
in tumor tissue was signiﬁcantly higher than that of DOX-zein
group (Po0.05) at 3 h after the injection. However, the DOX-
zein group maintained a relatively higher drug concentration
for a longer time in the tumor than DOX solution group. The
AUC of DOX-zein group and DOX solution group was
204.59 mg/mL  h and 18.71 mg/mL  h, respectively.
In non-tumor tissues (heart and lungs), the drug concentra-
tion in DOX-zein group was lower than in the DOX solution
group (Po0.05). The AUC of DOX-zein group and DOX
solution group in heart was 43.08 mg/mL  h and 57.40 mg/mL  h,
respectively. There were no signiﬁcant differences in liver,
spleen and kidney (P40.05). No DOX in DOX-zein group
was examined in liver after 12 h of injection. In spleen, the
Cmax of the DOX-zein group was nearly as large as that of
DOX solution group. In kidney, the drug concentration in
DOX-zein group was higher than that of the DOX solution
group after 3 h of injection, but the concentration of the DOX-
zein group started decreasing thereafter. These results indicate
that direct intratumoral injection signiﬁcantly enhanced the
distribution of DOX to the tumor and reduced the distribution
to the other organs.4. Conclusions
The present study describes a new drug delivery system of
DOX-loaded Zein in situ gels, in which a liquid state was
transformed into a semi-solid after intratumoral injection.
In vitro release of DOX from the gels could be extended up to
7 days. Efﬁcient accumulation of DOX in the tumor with
lower drug concentration in blood and normal organs resulted
in effective inhibition of tumor growth. This study demon-
strated that a sustained-release DOX-loaded in situ gel was
developed with enhanced anti-cancer efﬁcacy for CRC in vivo,
especially with reduced off-target side effects.
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